An Overview of Recent Possibilities in Pharmacotherapy of Diseases of the Oral Mucosa, Salivary Glands, and Periodontal Tissue
Authors:
R. Slezák 1; I. Lindrová 1,2; V. Buchta 3; V. Paulusová 1; Z. Šustová 1; O. Kopecký 1; Lenka Ryšková 3
Authors‘ workplace:
Stomatologická klinika LF UK a FN, Hradec Králové
1; Ústav klinické imunologie a alergologie LF UK a FN, Hradec Králové
2; Ústav klinické mikrobiologie LF UK a FN, Hradec Králové
3
Published in:
Česká stomatologie / Praktické zubní lékařství, ročník 113, 2013, 3, s. 64-73
Category:
Review Article
Věnováno prof. MUDr. Jiřímu Mazánkovi, DrSc., k významnému životnímu jubileu
Overview
Introduction:
A review of newer drugs for topical or systemic administration useful in contemporary dentistry in the therapy of diseases of periodontal tissue, oral mucous membrane, and salivary glands available in Czech Republic was given in this article.
Objectives:
There were discussed mouthrinses containing chlorhexidine in lower concentrations and/or oxidation agents associated with reduced dark discoloration of teeth and lingual mucosa. FotoSan 630 represents a system for photodynamic antimicrobial therapy using monochromatic light produced by light-emitting diods for the photoinitiation of the toluidine blue O as a photosensitizer. It is declared for the supportive topical treatment of plaque-induced periodontopathies, periimplant defects, dry socket, infected root canals and caries lesions. Hyaluronic acid contained in commercial gel products Aloclair and Gengigel, lubricative product Aequasyal, and gel product SineHerp are recommended in topical treatment of various less serious diseases of the oral mucosa and salivary glands. Drugs for systemic administration discussed here are antileukotriene immunomodulator montelucast, immunosuppressive and antiinflammatory drugs thalidomide and leflunomid. They are usable in the therapy of more serious mucosal diseases, mostly of autoimmune or uncertain origin. Caspofungin, micafungin and anidulafungin are modern echinocandin antimycotics for parenteral use indicated for treatment of severe mycotic infections, mostly candidiasis in altered individuals. Drugs for biological therapy declared as antitumorous and antiinflammatory agents already seldom used in dentistry are monoclonal antibodies rituximab, cetuximab, and erlotinib, potentially useful are also etanercept, infliximab and adalimumab. Botulotoxin is a neurotoxin of bacterial origin used at present in the therapy of various neurological disturbances in the head and neck area.
Key words:
periodontal tissue – oral mucous membrane – salivary glands – chlorhexidine – photodynamic antimicrobial therapy – hyaluronic acid – montelucast – thalidomide – leflunomide – echinocandins – biological therapy – botulotoxin
Sources
1. Allen, D. R., Davies, R., Bradshaw, B., Ellwood, R., Simone, A. J., Robinson, R., Mukerjee, C., Petrone, M. E., Chaknis, P., Volpe, A. R., Proskin, H. M.: Efficacy of a mouthrinse containing 0.05% cetylpyridinium chloride for the control of plaque and gingivitis: a 6-month clinical study in adults. Compend. Contin. Educ. Dent., roč. 19, 1998, Suppl. 2, s. 20–26.
2. Aloclair. http://www.sinclairispharma.com
3. Bečvář, R., Vencovský, J., Němec, P., Suchý, D., Procházková, L., Pavelka, K.: Doporučení České revmatologické společnosti pro léčbu revmatoidní artritidy. Účinnost a strategie léčby. Čes. Revmatol., roč. 15, 2007, č. 2, s. 16–32.
4. Blitzer, A., Benson, B. E., Guss, J.: Botulinum neurotoxin for head and neck disorders, 1. vyd. Thieme, New York Stuttgart, 2012.
5. Compilato, D., Colella, G., Fulfaro, F., Vicidomini, A., Campisi, G.: Effective use of sodium-hyaluronate spray formulation in oral mucositis. Oral Dis., roč. 18, 2012, Suppl. 1, s. 25.
6. Denning, D. W.: Echinocandin antifungal drugs. Lancet, roč. 362, 2003, s. 1142–1151.
7. EPOC. http://clinicaltrials.gov/show/NCT00402779 Erlotinib Prevention of Oral Cancer (EPOC).
8. Fusek, M., Vítek, L., Blahoš, J., Jr., Hajdúch, M., Ruml, T., a kol.: Biologická léčiva. Teoretické základy a klinická praxe, 1. vyd. Grada Publishing, a. s., Praha, 2012.
9. Gengigel http://www.ricerfarma.com
10. Hello, M., Barbarot, S., Bastuji-Garin, S., Revuz, J., Chosidow, O.: Use of thalidomide for severe recurrent aphthous stomatitis: A multicenter cohort analysis. Medicine (Baltimore), roč. 89, 2010, č. 3, s. 176–182.
11. Hodgson, T. A.: Adverse drug reactions: What is new? Oral Dis., roč. 18, 2012, Suppl. 1, s. 2.
12. Chrysomali, E., McCullough, M.: Updates of diagnostic and therapeutic dilemmas in oral medicine. Management of recurrent aphthous ulcers: What´s new? Oral Dis., roč. 18, 2012, Suppl. 1, s. 2.
13. Johannsen, A., Tellefsen, M., Wilkesjø, U., Johannsen, G.: Local delivery of hyaluronan as an adjunct to scaling and root planning in the treatment of chronic periodontitis. J. Periodontol., roč. 80, 2009, č. 9, s. 1492–1497.
14. Konopka, K., Goslinski, T.: Photodynamic therapy in dentistry. J. dent. Res., roč. 86, 2007, č. 8, s. 694–707.
15. Krejsek, J., Kopecký, O.: Modulace imunitního systému (kap.) In: Krejsek, J., Kopecký, O.: Klinická imunologie. Hradec Králové, Praha, Nucleus HK, 2004, 1. vyd., s. 804–810.
16. Mariette, X.: How does BAFF activate B cells in patients with autoimmune diseases? Arthritis Res. Therap., roč. 14, 2012, č. 1, s. 106. doi: 10.1186/ar3729
17. Martín-Piedra, M. A., Aguilar-Salvatierra, A., Herrera, D., Gómez-Moreno, G.: Effectiveness of a recent topical sialogogue in the management of drug-induced xerostomia. J. Clin. Exp. Dent., roč. 3, 2011, č. 4, s. e268–273.
18. McParland, H., Escudier, M., Mills, R., Cook, R. J., Kovacevic, T., Challacombe, S. J., Shirlaw, P. J.: Thalidomide for recalcitrant recurrent oral ulcerations: 20 years experience. Oral Dis., roč. 18, 2012, Suppl. 1, s. 27.
19. Meijer, J. M., Meiners, P. M., Vissink, A.: Effectiveness of rituximab treatment in primary Sjögren‘s syndrome: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum., roč. 62, 2010, č. 4, s. 960–968.
20. Mouly, S., Salom, M., Tillet, Y., Coudert, A.-C., Oberli, F., Preshaw, P. M., Desjonquères, S., Bergmann, J.-F.: Management of xerostomia in older patients: A randomised controlled trial evaluating the efficacy of a new oral lubricant solution. Drugs Aging, roč. 24, 2007, č. 11, s. 957–965.
21. Opstelten, W., Neven, A. K., Eekhof, J.: Treatment and prevention of herpes labialis. Canad. Fam. Phys., roč. 54, 2008, s. 1683–1687.
22. Pála, M.: Současná úloha chemoterapie a cílené biologické léčby v kurativní a paliativní léčbě spinocelulárního karcinomu hlavy a krku. Onkologie, roč. 6, 2012, č. 5, s. 257–259.
23. Pavelka K., Vencovský, J.: Doporučení České revmatologické společnosti pro léčbu revmatoidní artritidy. Čes. Revmatol., roč. 18, 2010, č. 4, s. 182–191.
24. Pijpe, J., van Imhoff, G. W., Spijkervet, F. K., Roodenburg, J. L., Wolbink, G. J., Mansour, K., Vissink, A., Kallenberg, C. G., Bootsma, H.: Rituximab treatment in patients with primary Sjögren‘s syndrome: An open-label phase II study. Arthritis Rheum., roč. 52, 2005, č. 9, s. 2740–2750.
25. Prolia®. Prolia product manager. Amgen Canada Inc., 2012.
26. Ryskova, L., Buchta, V., Slezak, R.: Photodynamic antimicrobial therapy. Centr. Eur. J. Biol., roč. 5, 2010, č. 4, s. 400–406.
27. Saji, G., Kisen, A.: Advanced noninvasive light-activate disinfection: Assessment of cytotoxicity on fibroblast versus antimicrobial activity against Enterococcus faecalis. J. Endod., roč. 33, 2007, č. 5, s. 599–602.
28. Sapna, N, Vandana, K. L.: Evaluation of hyaluronan gel (Gengigel®) as a topical applicant in the treatment of gingivitis. J. Invest. Clin. Dent., roč. 2, 2011, č. 3, s. 162–170.
29. Shetty, K.: Thalidomide in the management of recurrent aphthous ulcerations in patients who are HIV-positive: A review and case reports. Spec. Care Dent., roč. 25, 2005, č. 5, s. 236–241.
30. Schlafer, S., Vaeth, M., Hørsted-Bindslev, P., Frandsen, E. V. G.: Endodontic photoactivated disinfection using a conventional light source: An in vitro and ex vivo study. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., roč. 109, 2010, s. 634–641.
31. Sigush, B. W., Pfitzner, A., Albrecht, V., Glockmann, E.: Efficacy of photodynamic therapy on inflammatory signs and two selected periodontopathogenic species in a beagle dog model. J. Periodontol., roč. 76, 2005, s. 1100–1005.
32. Slezák, R., Šustová, Z., Nováková, V.: Pokroky ve farmakoterapii chorob ústní sliznice. Čes. Stomat., roč. 109, 2009, č. 1, s. 7–14.
33. Slezák, R., Ryšková, L., Paulusová, V., Šustová, Z., Berglová, I., Buchta, V.: Nové možnosti ve farmakoterapii chorob parodontu a ústní sliznice. Čes. Stomat., roč. 112, 2012, č. 1, s. 15–22.
34. Sreenivasan, P. K., Haraszthy, V. I., Zambon, J. J.: Antimicrobial efficacy of 0.05% cetylpyridinium chloride mouthrinses. Lett. Applic. Microbiol., 2012, Oct 8., doi: 10.1111/lam.12008. [Epub ahead of print].
35. Sukumar, S., Dřízhal. I.: Hyaluronic acid and periodontitis. Acta Medica (Hradec Králové), roč. 50, 2007, č. 4, s. 225–228.
36. Yagiela, J. A., Dowd, F. J., Johnson, B. S., Mariotti, A. J., Neidle, E. A.: Pharmacology of specific drug groups (part II), Special subjects in pharmacology and therapeutics (part III). In: Yagiela, J. A., Dowd, F. J., Johnson, B. S., Mariotti, A. J., Neidle, E. A.: Pharmacology and therapeutics for dentistry. Mosby Elsevier, 2011, 6. vyd., s. 78–744, s. 752–867.
37. Zakka, L. R., Shetty, S,. S., Ahmed, A. R.: Rituximab in the treatment of pemphigus vulgaris. Dermatol Ther (Heidelb.) roč. 2, 2012, č. 1. Epub 2012 Nov 15. Dostupné z: www.ncbi.nlm.nih.gov/pubmed/23205339.
Labels
Maxillofacial surgery Orthodontics Dental medicineArticle was published in
Czech Dental Journal
2013 Issue 3
Most read in this issue
- Negative Pressure in the Treatment of Odontogenic Inflammation
- Asymmetric Changes in Shape of Anterior Teeth - Dental Esthetics
- An Overview of Recent Possibilities in Pharmacotherapy of Diseases of the Oral Mucosa, Salivary Glands, and Periodontal Tissue
- Study of Cytokine Production in a Tisssue Culture of Human Macrophages Stimulated by Metal Ions